Reach Us +44-1647-403003
Colitis Due to Campylobacter jejuni/coli: Ceftriaxone is Not Effective | OMICS International | Abstract
ISSN: 2167-7182

Journal of Gerontology & Geriatric Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research Article

Colitis Due to Campylobacter jejuni/coli: Ceftriaxone is Not Effective

Stephane Emonet1*, Betim Redzepi1, Arnaud Riat2, Abdessalam Cherkaoui2, Benjamin A Lipsky1, Frederic Ris3 and Jacques Schrenzel1,2

1Service of Infectious Diseases, Department of Internal Medicine, Geneva University Hospitals, Switzerland

2Bacteriology laboratory, Department of Genetics and Laboratory Medicine, Geneva University Hospitals, Switzerland

3Service of Visceral Surgery, Department of Surgery, Geneva University Hospitals, Switzerland

*Corresponding Author:
Stephane Emonet
Service of Infectious Diseases, Department of Medical Specialties
Geneva University Hospitals, Gabrielle-Perret-Gentil 4
CH-1211 Geneva 14, Switzerland
Tel: +41022 3727323
Fax: +410223727312
E-mail: [email protected]

Received Date: May 08, 2017; Accepted Date: May 17, 2017; Published Date: May 20, 2017

Citation: Emonet S, Redzepi B, Riat A, Cherkaoui A, Lipsky BA, et al. (2017) Colitis Due to Campylobacter jejuni/coli: Ceftriaxone is Not Effective. J Gerontol Geriatr Res 6:426. doi: 10.4172/2167-7182.1000426

Copyright: © 2017 Emonet S, et al. This is an open-access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Ceftriaxone is often prescribed empirically for patients hospitalized with abdominal pain and fever. If stools culture from such a patient yields Campylobacter jejuni or Campylobacter coli (C. jejuni/coli), clinicians ask about its susceptibility to ceftriaxone, to which it is not routinely tested. We report a case of colitis that raised this question. As we couldn’t find the answer in the published literature, we investigated the sensitivity of strains of C. jejuni/coli to ceftriaxone in our hospital.

Methods: We conducted a retrospective study of all strains of C. jejuni and C. coli isolated from specimens of infected patients seen in our tertiary care university-affiliated hospital in Switzerland between March 2009 and December 2010. Campylobacter strains were identified to the species level with matrix-assisted laser desorption ionization - time of flight (MALDI-TOF) mass spectrometry and antimicrobial susceptibilities were determined by Etest.

Results: Among 108�C. jejuni and 14�C. coli isolates, only 1.6% were fully susceptible to ceftriaxone. Overall, 95.9% of our strains were susceptible to erythromycin but 52.5% of C. jejuni/coli were resistant to ciprofloxacin.

Conclusion: Our results suggest that ceftriaxone should be considered ineffective for the treatment of Campylobacter jejuni/coli infections, the major cause of gastro-enteritis in Europe. In the light of increasing resistance to fluoroquinolones, cases of severe Campylobacter colitis or bacteraemia may require a short course of macrolides.